PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios

Amylyx Pharmaceuticals, Inc. (AMLX)

Equity · Currency in USD · Last updated Oct 3, 2023
SummaryFinancials

Company Info

ISINUS03237H1014
CUSIP03237H101
SectorHealthcare
IndustryBiotechnology

Highlights

Market Cap$1.22B
EPS-$1.18
Revenue (TTM)$191.87M
Gross Profit (TTM)-$74.21M
EBITDA (TTM)-$80.29M
Year Range$17.80 - $41.93
Target Price$47.40
Short %17.71%
Short Ratio8.02

Share Price Chart


Loading data...

Performance

The chart shows the growth of an initial investment of $10,000 in Amylyx Pharmaceuticals, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-30.00%-20.00%-10.00%0.00%10.00%MayJuneJulyAugustSeptemberOctober
-34.84%
4.47%
AMLX (Amylyx Pharmaceuticals, Inc.)
Benchmark (^GSPC)

S&P 500

Compare to other instruments

Search for stocks, ETFs, and funds to compare with AMLX

Amylyx Pharmaceuticals, Inc.

Return

Amylyx Pharmaceuticals, Inc. had a return of -50.96% year-to-date (YTD) and -39.09% in the last 12 months.


PeriodReturnBenchmark
1 month-16.96%-5.04%
6 months-36.73%4.21%
Year-To-Date-50.96%11.29%
1 year-39.09%16.17%
5 years (annualized)0.16%-4.78%
10 years (annualized)N/AN/A

Monthly Returns Heatmap


JanFebMarAprMayJunJulAugSepOctNovDec
2023-15.74%-3.20%-13.06%-12.64%8.72%-8.06%-15.07%

Risk-Adjusted Performance

This table presents a comparison of risk-adjusted performance metrics for Amylyx Pharmaceuticals, Inc. (AMLX) and S&P 500 (^GSPC). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratioSortino ratioOmega ratioCalmar ratioUlcer Index
AMLX
Amylyx Pharmaceuticals, Inc.
-0.78
^GSPC
S&P 500
1.04

Sharpe Ratio

The current Amylyx Pharmaceuticals, Inc. Sharpe ratio is -0.78. A negative Sharpe ratio means that the risk-free rate is higher than the portfolio's return. This value does not convey any meaningful information.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00MayJuneJulyAugustSeptemberOctober
-0.78
0.87
AMLX (Amylyx Pharmaceuticals, Inc.)
Benchmark (^GSPC)

Dividend History


Amylyx Pharmaceuticals, Inc. doesn't pay dividends

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-60.00%-50.00%-40.00%-30.00%-20.00%-10.00%0.00%MayJuneJulyAugustSeptemberOctober
-55.73%
-9.02%
AMLX (Amylyx Pharmaceuticals, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below shows the maximum drawdowns of the Amylyx Pharmaceuticals, Inc.. A maximum drawdown is an indicator of risk. It shows a reduction in portfolio value from its maximum due to a series of losing trades.

The maximum drawdown since January 2010 for the Amylyx Pharmaceuticals, Inc. is 79.18%, recorded on May 11, 2022. It took 104 trading sessions for the portfolio to recover.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-79.18%Mar 1, 202250May 11, 2022104Oct 10, 2022154
-55.83%Jan 30, 2023162Sep 21, 2023
-17.59%Feb 2, 20228Feb 11, 20225Feb 18, 202213
-15.23%Dec 2, 202212Dec 19, 202223Jan 24, 202335
-13.39%Oct 27, 20228Nov 7, 202213Nov 25, 202221

Volatility Chart

The current Amylyx Pharmaceuticals, Inc. volatility is 10.41%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


5.00%10.00%15.00%20.00%MayJuneJulyAugustSeptemberOctober
10.41%
3.15%
AMLX (Amylyx Pharmaceuticals, Inc.)
Benchmark (^GSPC)